합성생물학 세계 시장 규모는 2024년 185억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 667억 달러에 달하고, 2025-2033년 15.3%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측했습니다. 현재 시장을 독점하고 있는 것은 북미가며, 2024년 시장 점유율은 41.8% 이상에 달했습니다. 북미의 우위는 탄탄한 생명공학 인프라, 연구 사업에 대한 투자 증가, 정부 지원책에 기인합니다.
주요 시장 성장 촉진요인 : 세계 합성생물학 시장은 유전자 편집 기술의 향상으로 인해 강력한 성장세를 보이고 있습니다.
주요 시장 동향 : 학계, 산업계, 정부 간 협력 체제가 혁신과 개발 역량을 강화하고 있습니다.
지리적 동향 : 생명공학에 대한 투자 확대로 북미가 시장을 주도하고 있습니다. 그러나 아시아태평양은 연구 활동과 정부의 이니셔티브이 활발해지면서 급성장하는 시장으로 부상하고 있습니다.
경쟁 환경: 주요 기업들은 기술 혁신을 촉진하고 복잡한 생물학적 문제를 해결하기 위해 연구 사업에 투자하고 있습니다. 합성 생물학 산업의 주요 시장 기업으로는 GenScript Biotech Corporation, Amyris Inc., Ginkgo Bioworks, Mammoth Biosciences, Novozymes, Merck KGaA 등이 있습니다.
과제와 기회: 과제로는 유전자변형 제품에 대한 윤리적, 안전적 우려를 들 수 있습니다. 그러나 규제를 준수하고 윤리적으로 배려한 혁신 제품을 개발할 수 있는 시장 개척의 기회는 이러한 과제를 극복할 수 있는 기회가 될 것으로 예측됩니다.
유전자 편집 기술의 발전
현재 CRISPR-Cas9와 같은 다양한 기술은 유전물질의 정확하고 효율적인 조작을 가능하게 함으로써 생물학 연구 분야를 향상시킬 수 있으며, 합성생물학 시장 수요를 강화하고 있습니다. 연구자들은 DNA 염기서열을 매우 정밀하게 설계, 편집, 조작하여 특정 기능에 따라 맞춤형으로 복잡한 합성 생물체를 쉽게 만들 수 있게 되었습니다. 이러한 기술 혁신은 유전자 치료를 통한 질병 치료, 효소나 바이오연료와 같은 귀중한 화합물을 생산할 수 있는 생명공학 생물의 창조와 같은 새로운 측면의 개발에 새로운 길을 열어 시장 확대에 기여하고 있습니다. 또한, 세계보건기구(WHO)는 인간 유전자 편집의 세계 거버넌스에 대한 획기적인 권고안을 발표하며 안전성, 유효성, 윤리성을 강조했습니다.
지속 가능한 솔루션에 대한 수요
다양한 산업 분야에서 지속 가능하고 친환경적인 솔루션에 대한 수요가 증가함에 따라 합성생물학 시장이 성장하고 있습니다. 합성생물학은 각 분야에 환경 영향 감소에 대한 요구를 충족시킬 수 있는 다양한 새로운 길을 제시하고 있습니다. 이에 따라 재생 가능한 자원에서 추출한 바이오플라스틱의 생산과 지속가능성을 향한 전 세계적인 움직임에 따라 탄소 배출량을 줄인 바이오연료의 개발이 시장 성장에 기여하고 있습니다. 이와는 별도로, 합성생물학은 오염물질을 무해화하여 환경을 정화하고 다양한 긴급한 생태학적 합병증에 대처하는 데 도움이 되는 생물학적 치료용 미생물을 생산할 수 있습니다. Vogue Business의 추산에 따르면, 매년 20-40%의 화장품이 폐기물로 버려지고, 업계는 연간 1,200억 개의 재활용이 어려운 포장재를 생산하고 있습니다. 또한, 화장품 원료 10가지 중 8가지가 지속 불가능한 방식으로 조달되고 있습니다. 이러한 문제를 해결하기 위해 합성생물학은 미생물의 DNA를 변형시켜 지속 가능한 소재를 만들어내고 있습니다. 합성생물학 시장 가격은 기술 혁신과 다양한 용도에 따른 급격한 성장을 반영하고 있습니다.
공동 생태계와 투자
학계, 산업계, 정부 간의 협력적 시너지 효과는 합성생물학 분야의 연구 활동을 촉진하는 환경을 조성합니다. 공동연구는 지식, 자산, 관점의 교환을 촉진하고 발명의 속도를 높입니다. 정부 당국은 연구 활동을 지원하기 위해 보조금과 자금을 자주 제공하고, 기존 기업과 신생 기업은 시장 성장을 가속하는 획기적인 벤처를 위해 서로 자원을 제공합니다. 여기에 더해 생명공학 스타트업에 대한 벤처 캐피탈 투자의 급증은 이 분야에 중요한 자본을 투입하여 싹이 트는 아이디어를 구체적인 제품 및 합성 생물학 시장 적용으로 성장시킵니다. 이러한 협력적 생태계는 연구, 혁신, 상업화의 순환을 유지하며 세계 합성생물학 시장을 발전시키고 있습니다.
또한, 합성생물학 시장의 미래는 독보적인 혁신, 지속 가능한 솔루션, 엄청난 성장 잠재력을 약속하며, Algal Bio와 같은 기업은 다양한 균주를 활용하여 새로운 솔루션을 혁신하고 있으며, Basecamp Research와 같은 신생기업은 머신러닝(ML)을 활용하여 합성 단백질 공학을 위한 자연계의 설계 원리를 해독하고 있습니다.
The global synthetic biology market size was valued at USD 18.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 66.7 Billion by 2033, exhibiting a CAGR of 15.3% from 2025-2033. North America currently dominates the market, holding a market share of over 41.8% in 2024. The dominance of North America can be attributed to robust biotechnology infrastructure, increasing investments in research operations, and supportive government initiatives.
Major Market Drivers: The global synthetic biology market is experiencing robust growth, driven by increasing improvements in gene editing technologies.
Key Market Trends: Collaborative efforts between academia, industry, and government are enhancing innovation and development capabilities.
Geographical Trends: North America dominates the market owing to the growing investments in biotechnology. However, Asia Pacific is emerging as a fast-growing market due to the increasing research activities and government initiatives in the region.
Competitive Landscape: Key players are investing in research operations to drive innovation and address complex biological challenges. Some of the major market players in the synthetic biology industry include GenScript Biotech Corporation, Amyris Inc., Ginkgo Bioworks, Mammoth Biosciences, Novozymes, Merck KGaA, among many others.
Challenges and Opportunities: Challenges include ethical and safety concerns related to genetically modified products. Nonetheless, opportunities for the market to develop regulatory-compliant, ethically considered innovations are projected to overcome these challenges.
Advancements in gene editing technologies
At present, various techniques like CRISPR-Cas9 are capable of improving the field of biology research by enabling precise and efficient manipulation of genetic material, strengthening the synthetic biology market demand. Researchers are designing, editing, and engineering DNA sequences with exceptional accuracy, facilitating the creation of intricate synthetic organisms customized according to specific functions. This innovation is opening new avenues for the development of novel aspects, like disease treatment through gene therapies and creation of bioengineered organisms capable of producing valuable compounds such as enzymes and biofuels, thus aiding in market expansion. Moreover, The World Health Organization (WHO) released groundbreaking recommendations for the global governance of human genome editing, emphasizing safety, efficacy, and ethics.
Demand for sustainable solutions
The rising demand for sustainable and environment-friendly solutions across various industries is propelling the synthetic biology market. Synthetic biology presents various new avenues for sectors to fulfill their demands to reduce the environmental impact of their operations. In line with this, the production of bioplastics extracted from renewable resources and the development of biofuels with reduced carbon emissions aligning with the global push towards sustainability are contributing to the market growth. Apart from this, synthetic biology is capable of creating microbes for bioremediation which is a method to detoxify contaminants or help clean up the environment and address various urgent ecological complications. Furthermore, synthetic biology is revolutionizing the sustainability efforts of the beauty sector. Vogue Business estimates that 20-40% of beauty products become waste annually, and the industry generates 120 billion units of difficult-to-recycle packaging yearly. Moreover, eight out of ten cosmetic ingredients are unsustainably sourced. To address these challenges, synthetic biology modifies microorganism DNA to create sustainable materials. The synthetic biology market price reflects rapid growth due to innovation and diverse applications.
Collaborative ecosystem and investment
The collaborative synergy between academia, industry, and government entities fosters a conducive environment for research operations within the synthetic biology field. Collaborations facilitate the exchange of knowledge, assets, and perspectives, thus quickening the rate of invention. Governing authorities frequently provide grants and funds to assist research endeavors, while established businesses and startups work together to pool resources for ground-breaking ventures that promote market growth. In addition to this, the surge in venture capital investments in biotechnology startups injects vital capital into the field, nurturing the growth of nascent ideas into tangible products and synthetic biology market application. This collaborative ecosystem sustains a cycle of research, innovation, and commercialization, propelling the global synthetic biology market forward.
Additionally, the future of the synthetic biology market promises unparalleled innovation, sustainability solutions, and expansive growth potential. Companies, such as Algal Bio utilize a diverse array of strains to innovate novel solutions, while startups like Basecamp Research employ machine learning (ML) to decipher the design principles of nature for synthetic protein engineering.
Oligonucleotide/oligo pools and synthetic DNA dominates the market
The growing demand for synthetic biology products, specifically oligonucleotide/oligo pools and synthetic DNA, is mainly fueled by the exponential growth in fields such as personalized medicine, gene therapy, and molecular diagnostics that have amplified the need for precise and customizable genetic materials. Additionally, the rise of synthetic biology startups and the democratization of gene editing technologies have made these products more accessible, empowering researchers across diverse disciplines to engage in innovative projects, thereby creating a favorable synthetic biology market outlook. For example, Synbio Technologies offers oligo pool synthesis for companies or clients who need to mass-produce short DNA strands, also known as oligonucleotides.
Next-generation sequencing (NGS) technology has become instrumental in deciphering complex biological information, facilitating the analysis of vast genetic data sets, and accelerating the discovery of novel genetic components, which in turn, is presenting lucrative market opportunities. Moreover, polymerase chain reaction (PCR) technology remains a cornerstone for DNA amplification, crucial in generating sufficient genetic material for various applications, from research to diagnostics. Besides this, genome editing technologies, particularly CRISPR-Cas9, hold immense promise for precision genetic modifications, driving advancements in gene therapies and customized genetic engineering. Bioprocessing technologies form a critical facet, enabling efficient large-scale production of bioengineered compounds, ranging from pharmaceuticals to biofuels. Companies are also investing and focusing on these aspects to create novel technologies. For example, Bayer and Mammoth Biosciences collaborated to develop a novel gene editing technology to unlock the full potential of CRISPR systems.
Additionally, the synthetic biology market statistics highlight a robust growth trajectory, driven by advancements in biotechnology and increasing investment in research and development.
The bolstering growth of the healthcare sector, wherein synthetic biology is used in the development of personalized medicines, gene therapies, and diagnostics, is contributing to the synthetic biology market growth. In addition, the numerous non-clinical or research applications of synthetic biology encompassing drug discovery, functional genomics, and biomolecule production, are fueling scientific exploration and market growth. Beyond healthcare, synthetic biology's expanding usage in biotech crops engineered for improved yield and resistance to pests is positively influencing the market. Furthermore, the increasing product adoption across the specialty chemicals industry, wherein bioengineered pathways create sustainable routes to produce high-value compounds is impelling the market growth. Apart from this, the growing use of synthetic biology in the biofuel sector to optimize microorganisms for efficient biofuel production is strengthening the market growth. Key market players are focusing on collaborating with each other to develop various novel technologies in synthetic biology. For instance, scientists led by Gerard Wright at McMaster University developed a synthetic biology platform for novel glycopeptide antibiotics (GPA) discovery. They engineered Streptomyces coelicolor as a chassis for GPA biosynthesis, overcoming challenges in cloning large biosynthetic gene clusters (BGCs) using an optimized transformation-associated recombination (TAR) system. The platform enabled the synthesis of corbomycin and the discovery of novel GPAs, expanding antibiotic candidates' repertoire.
North America exhibits a clear dominance, accounting for the largest synthetic biology market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The presence of a well-established research and innovation ecosystem in North America, characterized by leading academic institutions, cutting-edge biotechnology companies, and significant government investments, provides a fertile ground for advancements in synthetic biology. Moreover, the region's emphasis on R&D and technological innovation fosters collaborations that span academia and industry, driving the development of novel applications across sectors including healthcare, agriculture, and energy. In addition to this, the increasing focus on sustainable solutions and the demand for eco-friendly products align with synthetic biology's potential to offer greener alternatives. This, coupled with favorable regulatory frameworks that encourage biotechnology R&D, creates an environment conducive to the expansion of the North American synthetic biology market. In December 2022, the Investment Strategy by the Office of Strategic Capital (OSC) identifies synthetic biology as a priority technology area for private sector investment, aiming to attract capital and foster innovation in this field for national security purposes. The synthetic biology market overview reveals its rapid expansion, driven by innovation, research investment, and diverse applications.
The global synthetic biology market features a dynamic competitive landscape shaped by a blend of established players and innovative startups. Leading companies, with their significant financial resources and expansive research capabilities, dominate the market by offering a diverse range of synthetic biology products and services and highlighting how big is the synthetic biology market? These companies actively engage in collaborations, strategic partnerships, and mergers to enhance their offerings and expand their market reach. Furthermore, a surge in venture capital investments has catalyzed the emergence of agile startups, injecting fresh ideas and disruptive technologies into the field. The competitive arena is characterized by a focus on innovation, technology integration, and the ability to address diverse market segments, accentuating the evolutionary nature of the global synthetic biology market. On of the key players, Eurofins Genomics Blue Heron, introduced its IVT mRNA Synthesis Service, using cutting-edge technology for rapid and efficient mRNA transcript production. Tailored for various fields including molecular biology and gene therapy, it offers customizable synthesis with quick turnaround times and expert support, benefiting synthetic biology research and applications. According to synthetic biology market recent news, Aanika Biosciences is revolutionizing synthetic biology adoption across industries like food and agriculture through insurance. Their subsidiary, Aanika Insurance Services (AIS), offers cost-effective coverage, encouraging biologic use while ensuring risk mitigation and frequent sampling. Partnering with Western Growers Insurance Services, Aanika aims to expand its reach to farmers, distributors, and retailers.